John l. Flavin

All filings by John l. Flavin on record concern Pyxis Oncology, Inc., in the capacity of board member. In total, 4 filings cover trades dated from 13 October 2021 to 26 March 2024.

Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

On 28 March 2024 came the latest disclosure, a share grant in Pyxis Oncology, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.